Cytokines as biomarkers of nanoparticle immunotoxicity
M Elsabahy, KL Wooley - Chemical Society Reviews, 2013 - pubs.rsc.org
Nanoscale objects, whether of biologic origin or synthetically created, are being developed
into devices for a variety of bionanotechnology diagnostic and pharmaceutical applications …
into devices for a variety of bionanotechnology diagnostic and pharmaceutical applications …
[HTML][HTML] Social and economic burden of human leishmaniasis
I Okwor, J Uzonna - The American journal of tropical medicine and …, 2016 - ncbi.nlm.nih.gov
Leishmaniasis continues to pose a major public health problem worldwide. With new
epidemics occurring in endemic areas and the spread of the disease to previously free …
epidemics occurring in endemic areas and the spread of the disease to previously free …
A state-of-the-art review on solid lipid nanoparticles as a nanovaccines delivery system
M Assefi, M Ataeinaeini, A Nazari, A Gholipour… - Journal of Drug Delivery …, 2023 - Elsevier
In the design of vaccine generation, significant attempts have been made to produce novel
vaccines and, as well, to increase the effectiveness of available vaccines versus particular …
vaccines and, as well, to increase the effectiveness of available vaccines versus particular …
[HTML][HTML] Potential and applications of nanocarriers for efficient delivery of biopharmaceuticals
During the past two decades, the clinical use of biopharmaceutical products has markedly
increased because of their obvious advantages over conventional small-molecule drug …
increased because of their obvious advantages over conventional small-molecule drug …
Leishmaniasis: prevention, parasite detection and treatment
T Kobets, I Grekov, M Lipoldova - Current Medicinal Chemistry, 2012 - ingentaconnect.com
Leishmaniasis remains a public health problem worldwide, affecting approximately 12
million people in 88 countries; 50 000 die of it each year. The disease is caused by …
million people in 88 countries; 50 000 die of it each year. The disease is caused by …
New approaches from nanomedicine for treating leishmaniasis
V Gutiérrez, AB Seabra, RM Reguera… - Chemical Society …, 2016 - pubs.rsc.org
Leishmaniasis, a vector-borne disease caused by obligate intramacrophage protozoa,
threatens 350 million people in 98 countries around the world. There are already 12 million …
threatens 350 million people in 98 countries around the world. There are already 12 million …
Nanopharmaceuticals as a solution to neglected diseases: Is it possible?
The study of neglected diseases has not received much attention, especially from public and
private institutions over the last years, in terms of strong support for developing treatment for …
private institutions over the last years, in terms of strong support for developing treatment for …
Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities
R Sharma, U Agrawal, N Mody, SP Vyas - Biotechnology advances, 2015 - Elsevier
Mucosal sites serve as the main portal for the entry of pathogens and thus immunization
through mucosal routes can greatly improve the immunity. Researchers are continuously …
through mucosal routes can greatly improve the immunity. Researchers are continuously …
The novel treatments based on tissue engineering, cell therapy and nanotechnology for cutaneous leishmaniasis
Cutaneous leishmaniasis (CL) is a global public health issue. Conventional treatments have
substantial costs, side effects, and parasite resistance. Due to easy application and …
substantial costs, side effects, and parasite resistance. Due to easy application and …
An overview of biodegradable nanomaterials and applications in vaccines
X Yan, M Zhou, S Yu, Z Jin, K Zhao - Vaccine, 2020 - Elsevier
Vaccination is the most cost-effective and sustainable way to prevent and eliminate
infectious diseases. Compared with traditional vaccines, novel vaccines have better stability …
infectious diseases. Compared with traditional vaccines, novel vaccines have better stability …